Schott Pharma stock gains on JPMorgan Overweight rating and fresh SDAX high

Published on 09/16/2026 at 13:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Schott Pharma stock traded at EUR 23.15 on Xetra on September 16, 2026 after touching a 52-week high of EUR 23.85 the previous day. JPMorgan initiated coverage with an Overweight rating and a EUR 27.10 price target on September 15, 2026.

Pharma-Glasfläschchen auf Fließband in moderner Produktionsanlage — SCHOTT Pharma (DE000A3ENQ51) zeigt Glasfläschchen für Medikamente auf modernem Fließband in moderner sauberer Reinraumfertigungsanlage, Illustration mit AI erstellt.

Schott Pharma stock (ISIN DE000A3ENQ51) was quoted at EUR 23.15 on Xetra in early trading on September 16, 2026, close to the fresh 52-week high of EUR 23.85 reached on September 15, 2026 and supported by new analyst coverage from JPMorgan with an Overweight rating and a EUR 27.10 price target.

JPMorgan initiation drives recent momentum

According to finanzen.at on September 15, 2026, JPMorgan Chase started coverage of Schott Pharma with an Overweight rating and set a price target of EUR 27.10, highlighting the company’s role as a specialist for storage and delivery solutions for injectable medicines and an expected earnings growth potential of around 14 percent per year through 2029.

As n-tv reported on September 15, 2026, investors followed this positive analyst recommendation, with Schott Pharma shares rising by about 2.2 percent to EUR 23.10 at midday trading and climbing intraday by up to roughly 4 percent as the market digested the new Overweight call and the EUR 27.10 target.

In an additional summary of analyst views, finanzen.at lists Schott Pharma with several supportive ratings during August 2026, including Buy recommendations from UBS, Deutsche Bank, Berenberg and an Overweight rating from Barclays, indicating a broadly constructive analyst stance around the stock going into the JPMorgan initiation.

Stock near 52-week high after recent gains

Per Xetra trading data cited by finanzen.ch on September 16, 2026, Schott Pharma shares traded largely unchanged at EUR 23.15 on Xetra around 09:28 a.m. local time, after opening at EUR 23.30 and moving in an intraday range between EUR 23.10 and EUR 23.30.

The same price report states that the highest value reached by the stock over the past 52 weeks was EUR 23.85, recorded on September 15, 2026, meaning that the EUR 23.15 level on September 16, 2026 left the shares about 3 percent below the recent high while still marking a strong performance compared with earlier in the year, with a year-to-date gain of more than 50 percent indicated in index data referenced by MarketScreener.

According to the same MarketScreener overview on September 15, 2026, Schott Pharma’s Xetra closing price stood at EUR 23.15, up 2.43 percent over the preceding five trading days and about 53.31 percent higher year to date, underlining that the analyst-driven rally is building on an already strong price trend in the SDAX environment.

Latest quarterly figures and outlook

For fundamentals, investors look at the most recent quarterly figures that Schott Pharma presented for the latest quarter of fiscal 2026. As finanzen.ch notes, the company published its results for the most recent quarterly period on August 12, 2026, covering the latest business quarter of fiscal 2026; these results represent the current reporting base for analyst models and guidance, though detailed revenue and profit figures are not broken out in the brief news summary and therefore are not repeated here.

In addition, the same article highlights that Schott Pharma paid a dividend of EUR 0.180 per share for fiscal year 2025, while current estimates point to a slightly lower expected dividend of EUR 0.175 per share for the coming year, offering a modest yield component alongside the growth story in injectable drug packaging.

Analyst projections cited by finanzen.ch suggest that earnings per share for Schott Pharma in fiscal year 2026 could reach about EUR 0.982, implying solid earnings growth potential in line with JPMorgan’s assumption of mid-teens annual earnings expansion through 2029.

Upcoming annual results as next catalyst

Looking ahead, the next scheduled reporting event is also visible in recent data. The news summary at finanzen.ch refers to Schott Pharma’s plan to present its next set of financials for the fourth quarter 2026 around December 10, 2026, while an annual-results entry in the calendar section of MarketScreener likewise shows December 10, 2026 as the planned date for publication of annual 2026 results.

For investors, this upcoming December 10, 2026 reporting date is a key checkpoint, because the annual figures will either confirm or challenge the current consensus that Schott Pharma can deliver around EUR 0.982 earnings per share in 2026 and continue to grow earnings by double-digit percentages in subsequent years.

The combination of a visible next results date and supportive analyst coverage means that Schott Pharma stock currently trades with a clear pipeline of potential catalysts, where better-than-expected margins or stronger-than-modeled revenue in parenteral drug packaging could justify the upside embedded in the EUR 27.10 JPMorgan target relative to the EUR 23.15 Xetra level on September 16, 2026.

Schott Pharma stock price as of September 16, 2026

On September 16, 2026, Schott Pharma’s primary listing on Xetra showed the shares at EUR 23.15 around 09:28 a.m. local time, with an intraday high of EUR 23.30 and an intraday low of EUR 23.10, leaving the stock a few percent below the 52-week high of EUR 23.85 set on September 15, 2026 and maintaining a strong year-to-date gain in the SDAX index environment.